Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome

Annals of Pharmacotherapy

Volumn 40, Issue 5, 2006, Pages 972-976

  Pendleton, Robert ^a   Wheeler, Michelle M ^a,b   Rodgers, George M ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b Department of Psychiatry   (United States)

Author keywords

Antiphospholipid antibodies; Argatroban; Fondaparinux; Heparin induced thrombocytopenia

Indexed keywords

ARGATROBAN; ECARIN; HEPARIN; PHOSPHOLIPID ANTIBODY; THROMBIN; THROMBIN INHIBITOR;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING TIME; CASE REPORT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MONITORING; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOSIS;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HEPARIN; HUMANS; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; POLYSACCHARIDES; THROMBOCYTOPENIA; THROMBOSIS;

EID: 33646763480     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G319     Document Type: Article

References (25)

1. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-55.
2. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):311S-37S. Erratum 2005;127:416.
3. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-12.
4. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51.
5. Dager WE, White RH. Pharmacotherapy of heparin-induced thrombocytopenia. Expert Opin Pharmacother 2003;4:919-40.
6. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.
7. Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 2004;38:1383-8. Epub 6 Jul 2004. DOI 10.1345/aph.1D565
8. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003;33:173-83.
9. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced tnrombocytopenia. Arch Pathol Lab Med 2002;126:1415-23.
10. Perry SL, O'Shea SI, Ortel TL. Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time. Blood Coagul Fibrinolysis 2003;14:601-4.
11. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29.
12. Package insert. Argatroban (argatroban injection). Research Triangle Park, NC: GlaxoSmithKline, April 2005.
13. Swan SK, St. Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000;20:756-70.
14. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-56.
15. Package insert. Refludan (lepirudin injectable). Montville, NJ: Laboratories B, October 2004.
16. Badger NO, Butler K, Hallman LC. Excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia. Pharmacotherapy 2004;24:1800-3.
17. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol 2003;10:327-32.
18. Koopman MM, Buller HR. Short- and long-acting synthetic pentasaccharides. J Intern Med 2003;254:335-42.
19. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139-44.
20. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:114-7.
21. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999;5:259-66.
22. Dager WE, Andersen J, Nutescu E. Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. Pharmacotherapy 2004;24(7 pt 2):88S-94S.
23. Bradner JHR, Kuter DJ. Fondaparinux in the treatment of heparin-induced thrombocytopenia (abstract). Blood 2004;104(suppl):492a.
24. Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005;93:999-1000.
25. Lian EC, Chua L. Long-term use of fondaparinux in a patient with antiphospholipid syndrome, heparin-induced thrombocytopenia and refractoriness to coumarin (abstract 1775). Presented at: American Society of Hematology 45th Annual Meeting. San Diego, December 6-9, 2003.